A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment

Yoshida, Takashi; Tanaka, Toshiaki; Shindo, Tetsuya; Kyoda, Yuki; Hashimoto, Kimio; Kobayashi, Ko; Hasegawa, Tadashi; Masumori, Naoya

doi:10.1007/s13691-022-00536-z

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Single-agent immunotherapy or everolimus did not show convincing results in this cohort; however, recently, a partial response to nivolumab was reported in a 32 year-old female with MiT-RCC. 36 In contrast to our results for single-agent therapy, the combination of immunotherapy with another immunotherapeutic agent or a TKI led to a partial response in six instances (sunitinib plus sintilimab, axitinib plus pembrolizumab, axitinib plus avelumab, lenvatinib plus everolimus, and durvalumab plus tremelimumab). The first three combinations could potentially be an interesting focus for future research.…”

Section: Discussioncontrasting

confidence: 98%

Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study

Sprokkerieft,

van der Beek,

Spreafico

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

IntroductionIntroduction: Renal cell carcinoma (RCC) is a very rare pediatric renal tumor. Robust evidence to guide treatment is lacking and knowledge on targeted therapies and immunotherapy is mainly based on adult studies. Currently, the International Society of Pediatric Oncology–Renal Tumor Study Group (SIOP‐RTSG) 2016 UMBRELLA protocol recommends sunitinib for metastatic or unresectable RCC.MethodsThis retrospective study describes the effects of tyrosine kinase inhibitors (TKI), anti‐programmed cell death 1 (PD‐(L)1) monoclonal antibodies, and immunotherapeutic regimens in advanced‐stage and relapsed pediatric RCC.ResultsOf the 31 identified patients (0–18 years) with histologically proven RCC, 3/31 presented with TNM stage I/II, 8/31 with TNM stage III, and 20/31 with TNM stage IV at diagnosis. The majority were diagnosed with translocation type RCC (MiT‐RCC) (21/31) and the remaining patients mainly presented with papillary or clear‐cell RCC. Treatment in a neoadjuvant or adjuvant setting, or upon relapse or progression, included mono‐ or combination therapy with a large variety of drugs, illustrating center specific choices in most patients. Sunitinib was often administered as first choice and predominantly resulted in stable disease (53%). Other frequently used drugs included axitinib, cabozantinib, sorafenib, and nivolumab; however, no treatment seemed more promising than sunitinib. Overall, 15/31 patients died of disease, 12/31 are alive with active disease, and only four patients had a complete response. The sample size and heterogeneity of this cohort only allowed descriptive statistical analysis.ConclusionThis study provides an overview of a unique series of clinical and treatment characteristics of pediatric patients with RCC treated with targeted therapies.

show abstract

Section: Discussioncontrasting

confidence: 98%

Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study

Sprokkerieft,

van der Beek,

Spreafico

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…The patient underwent neoadjuvant therapy with VEGFR-TKI axitinib (5 mg orally once daily) as first-line treatment to reduce the size of the tumor lesion and metastasis. High PD-L1 expression was observed in the PD-L1 immunohistochemistry analysis ( Figure 2F ), which is consistent with previous studies that showed the correlation between PD-L1 expression levels in tumor tissues and the efficacy of PD-1 antibody treatment for TFE3 -rearranged RCC ( 10 , 11 ). Therefore, we administered the anti-programmed cell death-1 antibody tislelizumab (200 mg intravenously once every 3 weeks) targeted therapy.…”

Section: Case Presentationsupporting

confidence: 91%

A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report

Yang,

Dong,

Pan

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross hematuria. Computed Tomography (CT) imaging revealed the presence of a solid mass in the left kidney along with retroperitoneal metastasis. The patient received axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI), as first-line neoadjuvant therapy. Subsequent testing confirmed positive expression of programmed death-1 protein L1 (PDL1), leading to the addition of tislelizumab, a PD1 inhibitor, to the treatment regimen. After 8 months, the patient’s tumor size and metastases exhibited significant reduction, providing a favorable opportunity for subsequent surgical intervention. The tumor was classified as IV (pT3aN0M1) based on the pathologic stage of the American Joint Committee on Cancer (AJCC, 8th edition, 2017). The patient achieved long-term survival through combined systemic therapy involving surgery and neoadjuvant treatment. At the 30-month follow-up, there was no evidence of tumor recurrence or metastasis.

show abstract

Axitinib/nivolumab

2022

Reactions Weekly

View full text Add to dashboard Cite

A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment

Cited by 3 publications

References 14 publications

Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study

Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study

A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report

Axitinib/nivolumab

Contact Info

Product

Resources

About